Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

Abstract excerpt

Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia (CML). Here we examine predisposing factors underlying acquisition of KD mutations, evidence for acquisition of mutations before and during therapy, and whether the detection of a KD mutation universally implies resistance. We also provide a perspective on how...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Benzamides
• Share to Drug Resistance, Neoplasm
• Share to Fusion Proteins, bcr-abl